|
|
|
MIRA INFORM REPORT
|
Report No. : |
496799 |
|
Report Date : |
08.03.2018 |
IDENTIFICATION DETAILS
|
Name : |
SHIJIAZHUANG
NO. 4 PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
No. 288 Zhujiang Road, Hi-tech Development Zone, Shijiazhuang,
Hebei Province |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
28.06.1994 |
|
|
|
|
Unified Social Credit Code: |
911301001044060055 |
|
|
|
|
Legal Form : |
Wholly Foreign-Owned Enterprise |
|
|
|
|
Line of Business : |
Manufacturing
large volume injection, small volume injection, spray, tablet, hard capsule,
granule, mixture, dry suspension, inhalation preparation, liquid
disinfectant, detergent; selling its owned products; drug development and
technology transfer, pharmaceutical technology consulting, training and
services; own house rental |
|
|
|
|
No. of Employees : |
2,946 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A |
|
Credit Rating |
Explanation |
Rating Comments |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Slow but Correct |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous
Rating (30.09.2017) |
Current
Rating (31.12.2017) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s, China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role. China has implemented reforms in a gradualist fashion, resulting in efficiency gains that have contributed to a more than tenfold increase in GDP since 1978. Reforms began with the phaseout of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, growth of the private sector, development of stock markets and a modern banking system, and opening to foreign trade and investment. China continues to pursue an industrial policy, state support of key sectors, and a restrictive investment regime. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2016 stood as the largest economy in the world, surpassing the US in 2014 for the first time in modern history. China became the world's largest exporter in 2010, and the largest trading nation in 2013. Still, China's per capita income is below the world average.
After keeping its currency tightly linked to the US dollar for years, China in July 2005 moved to an exchange rate system that references a basket of currencies. From mid-2005 to late 2008, the renminbi appreciated more than 20% against the US dollar, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing announced it would allow a resumption of gradual liberalization. From 2013 until early2015, the renminbi (RMB) appreciated roughly 2% against the dollar, but the exchange rate fell 13% from mid-2015 until end-2016 amid strong capital outflows in part stemming from the August 2015 official devaluation; in 2017 the RMB resumed appreciating against the dollar – roughly 7% from end-of-2016 to end-of-2017. From 2013 to 2017, China had one of the fastest growing economies in the world, averaging slightly more than 7% real growth per year. In 2015, the People’s Bank of China announced it would continue to carefully push for full convertibility of the renminbi, after the currency was accepted as part of the IMF’s special drawing rights basket. However, since late 2015 the Chinese Government has strengthened capital controls and oversight of overseas investments to better manage the exchange rate and maintain financial stability.
The Chinese Government faces numerous economic challenges including: (a) reducing its high domestic savings rate and correspondingly low domestic household consumption; (b) managing its high corporate debt burden to maintain financial stability; (c) controlling off-balance sheet local government debt used to finance infrastructure stimulus; (d) facilitating higher-wage job opportunities for the aspiring middle class, including rural migrants and college graduates, while maintaining competitiveness; (e) dampening speculative investment in the real estate sector without sharply slowing the economy; (f) reducing industrial overcapacity; and (g) raising productivity growth rates through the more efficient allocation of capital and state-support for innovation. Economic development has progressed further in coastal provinces than in the interior, and by 2016 more than 169.3 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of China’s population control policy known as the “one-child policy” - which was relaxed in 2016 to permit all families to have two children - is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and urbanization. The Chinese Government is seeking to add energy production capacity from sources other than coal and oil, focusing on natural gas, nuclear, and clean energy development. In 2016, China ratified the Paris Agreement, a multilateral agreement to combat climate change, and committed to peak its carbon dioxide emissions between 2025 and 2030.
The government's 13th Five-Year Plan, unveiled in March 2016, emphasizes the need to increase innovation and boost domestic consumption to make the economy less dependent on government investment, exports, and heavy industry. However, China has made more progress on subsidizing innovation than rebalancing the economy. Beijing has committed to giving the market a more decisive role in allocating resources, but the Chinese Government’s policies continue to favor state-owned enterprises and emphasize stability. Chinese leaders in 2010 pledged to double China’s GDP by 2020, and the 13th Five Year Plan includes annual economic growth targets of at least 6.5% through 2020 to achieve that goal. In recent years, China has renewed its support for state-owned enterprises in sectors considered important to "economic security," explicitly looking to foster globally competitive industries. Chinese leaders also have undermined some market-oriented reforms by reaffirming the “dominant” role of the state in the economy, a stance that threatens to discourage private initiative and make the economy less efficient over time. The slight acceleration in economic growth in 2017—the first such uptick since 2010—gives Beijing more latitude to pursue its economic reforms, focusing on financial sector deleveraging and its Supply-Side Structural Reform agenda, first announced in late 2015.
|
Source
: CIA |
Company
name and address
|
COMPANY NAME |
Shijiazhuang No. 4 Pharmaceutical Co., Ltd. |
|
CURRENT ADDRESS |
No. 35 Huitong Road,
Shijiazhuang, Hebei Province 052165 PR China |
|
REGISTERED
ADDRESS |
No. 288 Zhujiang Road, Hi-tech
Development Zone, Shijiazhuang, Hebei Province |
|
TEL. NO. |
86 (0)
15028103937/15075125795/311-67167130 |
|
FAX NO. |
86 (0) 311-86012404 |
EXECUTIVE
SUMMARY
Date of Registration : june 28, 1994
Unified social credit code : 911301001044060055
LEGAL FORM : Wholly
foreign-owned enterprise
REGISTERED CAPITAL : CNY 400,000,000
staff : 2,946
BUSINESS CATEGORY : MANUFACTURING & TRADING
Revenue : N/A
EQUITIES : N/A
WEBSITE : www.sjzsiyao.com
E-MAIL : market@sjzsiyao.com
PAYMENT : SLOW BUT CORRECT
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND : FAIRLY STEADY
GENERAL REPUTATION : AVERAGE
Adopted abbreviations (as follows)
SC -
Subject Company (the company inquired by you)
N/A – Not
available
CNY –
China Yuan Ren Min Bi
OPERATIONAL
TREND & GENERAL REPUTATION
This section aims at indicating the relative positions of SC
in respect of its operational trend & general reputation
Operational Trend:- General
Reputation:-
Upward Excellent
Steady Good
Fairly Steady Fairly
Good
Ordinary Average
Fair Fair
Stagnant Detrimental
Downward Not
known
Not known Not
yet be determined
Not yet be determined
LEGAL
STATUS & HISTORY
SC was established as wholly
foreign-owned enterprise of PRC with State Administration of Industry
& Commerce (SAIC) under unified social credit code: 911301001044060055.
SC’s Import and Export Enterprise
Code: 1300104406005
SC’s registered capital: CNY 400,000,000
SC’s paid-in capital: CNY 400,000,000
Registration Change Record:
|
Date |
Change of Contents |
Before the change |
After the change |
|
2014-8-6 |
Registered Capital |
CNY 260,000,000 |
CNY 400,000,000 |
|
-- |
Registration No./ Unified
Social Credit Code |
130000400001707 |
911301001044060055 |
Current Co search indicates SC’s shareholders & chief
executives are as follows:-
|
Name of Shareholder (s) |
% of Shareholding |
|
New Orient Investments
Pharmaceutical Holding (Hong Kong) Limited |
100 |
SC’s Chief Executives:-
|
Position |
Name |
|
Legal Representative, Chairman
and General Manager |
Qu
Jiguang |
|
Director |
Su Xuejun |
|
Gao Shuping |
|
|
Yin Dianshu |
|
|
Wu Hengyao |
|
|
Shi Jianhui |
|
|
Meng Guo |
RECENT
DEVELOPMENT
No recent development was found during our checks at
present.
SHAREHOLDER
CHART & BACKGROUND
Name %
of Shareholding
New Orient Investments
Pharmaceutical Holding (Hong Kong) Limited 100
------------------------------------------------
CR No.: F0018280
Date of Incorporation: 11 April
2011
Active Status: Live
MANAGEMENT
Qu Jiguang), Legal Representative, Chairman and General Manager
--------------------------------------------------------------------------------------------------
Ø Gender:
M
Ø Nationality:
China
Ø Qualification:
University
Ø Working experience
(s):
At present, working in SC
as legal representative, chairman and general manager
Director
-----------
Su Xuejun
Gao Shuping
Yin Dianshu
Wu Hengyao
Shi Jianhui
Meng Guo
BUSINESS
OPERATION
SC’s registered business scope
includes manufacturing large volume injection, small volume
injection, spray, tablet, hard capsule, granule, mixture, dry suspension,
inhalation preparation, liquid disinfectant, detergent; selling its owned
products; drug development and technology transfer, pharmaceutical technology
consulting, training and services; own house rental.
SC is
mainly engaged in manufacturing and selling injection, spray, tablet, hard
capsule, granule, etc
SC’s
products mainly include: infusions, capsules, granules, tablets, oral liquids
and etc.
SC sources its materials 100% from domestic market, mainly Hebei. SC sells 70% of its products in domestic market, and 30% to overseas market, mainly USA, Europe, Mid East, Southeast Asia, etc.
The
buying terms of SC include Check, T/T and Credit of 30-60 days. The payment
terms of SC include T/T, L/C and Credit of 30-60 days.
*Major Customers*
==============
Jaspharm
Cia. Ltda.
J P S
Distribuciones Eirl
Staff & Office:
--------------------------
SC is
known to have approx. 2,946 staff
at present.
SC
owns an area as its operating office and factory, but the detailed information
is unknown.
RELATED
COMPANY
SC is known to
have the following subsidiaries at present,
Anhui Guangxiang Pharmaceutical Co. Ltd.
Hebei Guangxiang Pharmaceutical Co. Ltd.
Hebei Guangxiang Logistics Co., Ltd.
Hebei Jinmen Pharmaceutical Import and Export Co., Ltd.
Hebei Guangxiang Pharmaceutical Technology Co., Ltd.
PAYMENT
Overall payment appraisal:
( ) Excellent ( )
Good (X) Average ( ) Fair ( ) Poor ( ) Not yet be determined
The appraisal serves as a reference to reveal SC's payments
habits and ability to pay. It is based
on the 3 weighed factors: Trade payment experience (through current enquiry
with SC's suppliers), our delinquent payment records and our debt collection
record concerning SC.
Trade payment experience: SC
did not provide any name of trade/service suppliers and we have no other
sources to conduct the enquiry at present.
Delinquent payment record: None
in our database.
Debt collection record: No
overdue amount owed by SC was placed to us for collection within the last 6
years.
BANKING
Basic Bank:
Industrial and Commercial Bank of China Chang’an Sub-branch
AC#: 0402020419300428307
FINANCIALS
The financials of SC is not
available in local SAIC, and SC also refused to release the details.
CONCLUSIONS
SC is considered large-sized in its line with a development
history of 24 years.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.96 |
|
|
1 |
INR 90.34 |
|
Euro |
1 |
INR 80.75 |
|
CNY |
1 |
INR 10.28 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VIV |
|
|
|
|
Report Prepared
by : |
SYL |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low risk
of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably on
secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the business
is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.